Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clinicians. 2024;74(3):229–63. https://doi.org/10.3322/caac.21834.
Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023–75. https://doi.org/10.1016/S0140-6736(17)33326-3.
Article PubMed PubMed Central Google Scholar
De Koning HJ, Van Der Aalst CM, De Jong PA, et al. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. n Engl J Med. 2020;382(6):503–13. https://doi.org/10.1056/NEJMoa1911793.
The National Lung Screening Trial Research Team.. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. n Engl J Med. 2011;365(5):395–409. https://doi.org/10.1056/NEJMoa1102873.
Article PubMed Central Google Scholar
Kauczor HU, Von Stackelberg O, Nischwitz E, et al. Strengthening lung cancer screening in Europe: fostering participation, improving outcomes, and addressing health inequalities through collaborative initiatives in the SOLACE consortium. Insights Imaging. 2024;15(1):252. https://doi.org/10.1186/s13244-024-01814-5.
Article PubMed PubMed Central Google Scholar
Ledda RE, Funk GC, Sverzellati N. The pros and cons of lung cancer screening. Eur Radiol. 2024;35(1):267–75. https://doi.org/10.1007/s00330-024-10939-6.
Article PubMed PubMed Central Google Scholar
Silva M, Prokop M, Jacobs C, et al. Long-Term Active Surveillance of Screening Detected Subsolid Nodules is a Safe Strategy to Reduce Overtreatment. J Thorac Oncol. 2018;13(10):1454–63. https://doi.org/10.1016/j.jtho.2018.06.013.
Scholten ET, De Jong PA, De Hoop B, et al. Towards a close computed tomography monitoring approach for screen detected subsolid pulmonary nodules? Eur Respir J. 2015;45(3):765–73. https://doi.org/10.1183/09031936.00005914.
Meza R, Cao P, Jeon J, et al. Impact of Joint Lung Cancer Screening and Cessation Interventions Under the New Recommendations of the U.S. Preventive Services Task Force. J Thorac Oncol. 2022;17(1):160–6. https://doi.org/10.1016/j.jtho.2021.09.011.
Cadham CJ, Jayasekera JC, Advani SM, et al. Smoking cessation interventions for potential use in the lung cancer screening setting: A systematic review and meta-analysis. Cancer Treat Res. 2019;135:205–16. https://doi.org/10.1016/j.lungcan.2019.06.024.
Jonas DE, Reuland DS, Reddy SM, et al. Screening for Lung Cancer With Low-Dose Computed Tomography: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2021;325(10):971. https://doi.org/10.1001/jama.2021.0377.
Rasmussen JF, Siersma V, Malmqvist J, Brodersen J. Psychosocial consequences of false positives in the Danish Lung Cancer CT Screening Trial: a nested matched cohort study. Bmj Open. 2020;10(6):e34682. https://doi.org/10.1136/bmjopen-2019-034682.
Article PubMed PubMed Central Google Scholar
Callister MEJ, Sasieni P, Robbins HA. Overdiagnosis in lung cancer screening. Lancet Respir Med. 2021;9(1):7–9. https://doi.org/10.1016/S2213-2600(20)30553-1.
Article PubMed PubMed Central Google Scholar
Brodersen J, Schwartz LM, Heneghan C, O’Sullivan JW, Aronson JK, Overdiagnosis WS. what it is and what it isn’t. bmj Ebm. 2018;23(1):1–3. https://doi.org/10.1136/ebmed-2017-110886.
Pozzessere C, Von Garnier C, Beigelman-Aubry C. Radiation Exposure to Low-Dose Computed Tomography for Lung Cancer Screening: Should We Be Concerned? Tomography. 2023;9(1):166–77. https://doi.org/10.3390/tomography9010015.
Article PubMed PubMed Central Google Scholar
Field JK, Vulkan D, Davies MPA, Duffy SW, Gabe R. Liverpool Lung Project lung cancer risk stratification model: calibration and prospective validation. Thorax. 2021;76(2):161–8. https://doi.org/10.1136/thoraxjnl-2020-215158.
Bach PB, Kattan MW, Thornquist MD, et al. Variations in Lung Cancer Risk Among Smokers. Jnci: J Natl Cancer Inst. 2003;95(6):470–8. https://doi.org/10.1093/jnci/95.6.470.
Tammemagi MC, Schmidt H, Martel S, et al. Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study. Lancet Oncol. 2017;18(11):1523–31. https://doi.org/10.1016/S1470-2045(17)30597-1.
Chang GC, Chiu CH, Yu CJ, et al. Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan: a prospective cohort study. Lancet Respir Med. 2024;12(2):141–52. https://doi.org/10.1016/S2213-2600(23)00338-7.
McRonald FE, Yadegarfar G, Baldwin DR, et al. The UK Lung Screen (UKLS): Demographic Profile of First 88,897 Approaches Provides Recommendations for Population Screening. Cancer Prev Res. 2014;7(3):362–71. https://doi.org/10.1158/1940-6207.CAPR-13-0206.
Snoeckx A, Silva M, Prosch H, et al. Lung cancer screening with low-dose CT: definition of positive, indeterminate, and negative screen results. A nodule management recommendation from the European Society of Thoracic Imaging. Eur Radiol. 2025; https://doi.org/10.1007/s00330-025-11648-4.
Article PubMed PubMed Central Google Scholar
International Early Lung Cancer Action Program: Screening Protocol https://www.ielcap.org/wp-content/uploads/2023/05/ielcap-protocol.pdf. Accessed 22 Aug 2025.
Christensen J, Prosper AE, Wu CC, et al. ACR Lung-RADS v2022: Assessment Categories and Management Recommendations. Chest. 2024;165(3):738–53. https://doi.org/10.1016/j.chest.2023.10.028.
Prokop M, Schaefer-Prokop C, Jacobs C, et al. Aggressiveness-guided nodule management for lung cancer screening in Europe—justification for follow-up intervals and definition of growth. Eur Radiol. 2025; https://doi.org/10.1007/s00330-025-11647-5.
Article PubMed PubMed Central Google Scholar
Baldwin DR, Callister ME. The British Thoracic Society guidelines on the investigation and management of pulmonary nodules. Thorax. 2015;70(8):794–8. https://doi.org/10.1136/thoraxjnl-2015-207221.
Oudkerk M, Liu S, Heuvelmans MA, Walter JE, Field JK. Lung cancer LDCT screening and mortality reduction—evidence, pitfalls and future perspectives. Nat Rev Clin Oncol. 2021;18(3):135–51. https://doi.org/10.1038/s41571-020-00432-6.
Chandrika S, Yarmus L. Recent developments in advanced diagnostic bronchoscopy. Eur Respir Rev. 2020;29(157):190184. https://doi.org/10.1183/16000617.0184-2019.
Article PubMed PubMed Central Google Scholar
Ledda RE, Milanese G, Revel MP, Snoeckx A. Pros and cons of reporting incidental findings in lung cancer screening. Eur Radiol. 2025; https://doi.org/10.1007/s00330-025-11580-7.
Article PubMed PubMed Central Google Scholar
Dyer DS, White C, Thomson CC, et al. A Quick Reference Guide for Incidental Findings on Lung Cancer Screening CT Examinations. J Am Coll Radiol. 2023;20(2):162–72. https://doi.org/10.1016/j.jacr.2022.08.009.
O’Dowd EL, Tietzova I, Bartlett E, et al. ERS/ESTS/ESTRO/ESR/ESTI/EFOMP statement on management of incidental findings from low dose CT screening for lung cancer. Eur Respir J. 2023;62(4):2300533. https://doi.org/10.1183/13993003.00533-2023.
Lancaster HL, Zheng S, Aleshina OO, et al. Outstanding negative prediction performance of solid pulmonary nodule volume AI for ultra-LDCT baseline lung cancer screening risk stratification. Cancer Treat Res. 2022;165:133–40. https://doi.org/10.1016/j.lungcan.2022.01.002.
Zhao Y, De Bock GH, Vliegenthart R, et al. Performance of computer-aided detection of pulmonary nodules in low-dose CT: comparison with double reading by nodule volume. Eur Radiol. 2012;22(10):2076–84.
Comments (0)